Obesity. diet, exercise and drugs june 2012
Upcoming SlideShare
Loading in...5
×
 

Obesity. diet, exercise and drugs june 2012

on

  • 1,138 views

 

Statistics

Views

Total Views
1,138
Views on SlideShare
898
Embed Views
240

Actions

Likes
0
Downloads
9
Comments
0

9 Embeds 240

http://peninsulaendocrine.blogspot.co.uk 103
http://peninsulaendocrine.blogspot.com 69
http://peninsulaendocrine.blogspot.com.au 57
http://peninsulaendocrine.blogspot.in 4
http://peninsulaendocrine.blogspot.ro 2
http://peninsulaendocrine.blogspot.ie 2
http://peninsulaendocrine.blogspot.ca 1
http://www.google.com.au 1
http://peninsulaendocrine.blogspot.pt 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Israeli study Dietetic input wk 1,3,5,7 then every 6 /52 for 18 sessions of 90 minutes, 6 extra motivational phone calls
  • May be overestimate as based on completers
  • Diastiloc BP drop of 2mmHG in Cochrane and TG and Glucose both down by 0.2mmol/l Donelly and colleagues women did less exercise in the 45 mins with lower energy output Lee et all Cooper clinic Dallas-obesrvational Cohort Church et al Aerobic Centre Longitudinal Study-Cooper Clinic In LookAHEAD only 1.8% of those in highest tertile of waist circumference were in highest tertile for fitness
  • Jakicic study 201 overweight/obese women in 4 different exercise treatment strategies followed for 24 months
  • Ball Paper- frequent (>1x week)take away food consumption also increased risk of weight gain French-139 men, 1913 women in 32 companies particpating in a smoking cessation and weight control study
  • Gibala-Hamilton Ontario McGee Melbourne
  • Weight control is more difficult to achieve in patients with type 2 diabetes Weight loss is of primary importance in the management of type 2 diabetes. However, weight loss is difficult to achieve in these patients. [1,2] The mechanisms underlying the disparate weight loss are not fully understood but may include altered regulation of energy balance or reduction in glycosuria associated with improved glycaemic control. [1] References 1. Khan MA, St. Peter JV, Breen GA, et al. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res 2000; 8: 43–8 2. Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563–6
  • Odd extension reported by Lean Obesity 2010 SanDiego Afer 52 weeks everyone wnet on to liraglutide 2.4 mg then 3.0mg except those on orlistat Still up to 50% patietns either did not achoieve 5% weight loss or withdrew from taking the drug
  • Topiramate acts on slow sodium channels, kainate/AMPA glutamate receptors, GABA receptors, ? Effec ton metabolic rate Phetnermine withdrawn in UK 2000, short term use < 12/52 USA/Aus
  • 50% completed 56 weeks in COR -1 1742 patients similar results to COR Diabetes 2 different doses of naltrexone at 16 and 32 mg COR-1
  • Schwarz Nature vol 404 6 April 2000
  • NPY/AGRP and POMC/CART neurons in the arcuate nucleus, adjacent to the third ventricle, are first-order neurons in the hypothalamic response to the circulating adiposity signals insulin and leptin. a , Populations of first-order NPY/AGRP (green) and POMC/CART (red) neurons in the arcuate nucleus (ARC) are regulated by leptin and project to the PVN and to the LHA and PFA, which are locations of second-order hypothalamic neuropeptide neurons involved in the regulation of food intake and energy homeostasis Locations of candidate second-order neurons involved in the hypothalamic response to insulin and leptin adiposity signalling. a , Diagram showing neuronal axons containing NPY and -MSH from the arcuate nucleus (ARC) innervating the PVN, LHA and PFA (adjacent to the fornix). Candidate second-order neurons include those that express TRH, CRH and oxytocin (OXY) in the PVN (which cause anorexia), and neurons that express orexins and MCH in the PFA and LHA (which increase feeding).
  • Figure 6 Neuroanatomical model of pathways by which adiposity signals, leptin (secreted by adipocytes) and insulin (secreted by the endocrine pancreas in proportion to adiposity), interact with central autonomic circuits regulating meal size. Leptin and insulin are proposed to stimulate a catabolic pathway (POMC/CART neurons) and inhibit an anabolic pathway (NPY/AGRP neurons) that originates in the arcuate nucleus (ARC). These pathways project to the PVN and LHA/PFA, where they make connections with central autonomic pathways that project to hindbrain autonomic centres that process satiety signals. Afferent input related to satiety from the liver, gastrointestinal tract and from peptides such as CCK are transmitted through the vagus nerve and sympathetic fibres to the nucleus of the solitary tract (NTS), where they are integrated with descending hypothalamic input. Net neuronal output from the NTS and other hindbrain regions leads to the termination of individual meals, and is potentiated by catabolic projections from the PVN and inhibited by input from the LHA/PFA. Reduced input from adiposity signals (for example, during diet-induced weight loss), therefore, increases meal size by reducing brainstem responses to satiety signals. Not shown are ascending projections from hindbrain to forebrain that may also contribute to adaptive changes in food intake.

Obesity. diet, exercise and drugs june 2012 Obesity. diet, exercise and drugs june 2012 Presentation Transcript

  • Obesity. Diet, Exercise and Drugs. How much pain? How muchPatrick English gain?Consultant Physician. Derriford
  • Overview• Dietary intervention – Effectiveness of major studied interventions• Exercise – Major studied interventions – Metabolic effects – Weight loss effects• CombinedStrategies-LookAHEAD• Pharmacotherapy – GLP-1 and Orlistat – Newer agents
  • Dietary interventions• Energy restriction – VLCD – LCD – Liquid meal replacements• Mediterranean• Low CHO/Low GI/Low fat/Macronutrient restriction/freedom
  • Dietary interventions• Goal is maintenance of weight loss achieved• Few studies of good quality and long duration• Energy restriction is ultimately the key
  • Low GI: Cochrane Review 2009. Lowglycaemic index or low glycaemic load diets for overweight and obesity • 6 RCTs Low GI vs standard with 202 participants, 5/52-26/52 duration • Possible small benefit with low GI – 1 kg greater WL at 6/12 – TC -0.22mM – LDL -0.24mM • unconvincing
  • Low CHO. Obesity Reviews 2009. Hession• Low CHO/High protein vs Low fat/Low Cal/Higher CHO• Systematic review 2000-2007• Adults , Mean BMI ≥28, duration > 6/12• 13 studies-longest 36/12, total number 1022 patients• Attrition rate 36%• At 6/12 favours Low CHO -4.02kg• At 12/12 Favours low CHO -1.05 kg• In the one trial to go to 3 yrs-no difference
  • Mediterranean: Shai NEJM 2008• Low CHO vs LF vs Med diet (which was as low in fat as LF)• 2yrs• 322 patients, 52 yo, BMI 31• Adherence 95.4% 1yr, 84.6% 2y• WL in LF vs Low CHO vs Med = 2.9kg vs 4.7kg* vs 4.4 kg*• inT2DM glucose  1.8mmol/L in Med with  HOMA-IR
  • Longer term studies: Douketis IJO 2005• Systematic review-BMI ≥ 25, prespecified approved WL intervention, clinical trial, > 2yrs, > 100 subjects• 16 dietary/lifestyle interventions, 6 with FU = 4yrs. Results based on completers• 5698 subjects, mean age:40-59, Mean wt 78-116kg, Attrition 31-64%• 13 studies split induction (3-18/12) then maintenance, 3 studies just induction over 2-4 yrs• <5kg WL after 2-3yrs (3.5±2.4kg, range 0.9-10kg)• <5kg after 4-7 yrs (3.6±2.6kg, range 1.8-10kg)
  • Liquid meal replacements. Flechtner-Mors Ob Res 2000• 100 patients BMI-25-40• 1200-1500 kcal/d restriction with diet vs meal replacement shakes x 2 for 12/52• 1 x meal replacement shake and snack daily as part of maintenance 4 yrs• Attrition of 42 patients at 2 yrs, 32 persuaded to rejoin• WL 1.3 vs 7.1kg 12/52, 4.1kg vs 9.5kg at 4 y, 75% FU• SBP  13.3 mmHg in intensive gp, glucose fell in both by 0.6-0.65mM
  • Take Home – Different dietary composition little effect long term though suggestive for Low CHO/Med – Adherence and energy content most important – Adherence low with severely CHO restricted diets at 1 year (< 50% vs 60=% with other approaches) – Interventions with large weight loss up front with lifestyle change subsequently may have a bigger effect1. – Dietary counselling JAMA 2005; modest effect Int Med Astrup Lancet 2004; 364:897-9 2. Dansinger has a 293:43-53 3. Dansinger Ann as2007: 147:41-50 4. Astrup Obes Rev 2000; 1:17-19 5. Anderson Am J Clin Nut 2001; 74:579-84 stand alone intervention (-1.9 BMI units 3)
  • Exercise/Activity-Studied interventions• Resistance training• Aerobic training – Long duration – Short duration• HIT
  • Metabolic/Weight losseffects of Resistance Training• Resistance training – Poorly studied for weight loss2 – Intensity and duration not clearly defined – Better studied in type 2 diabetes and lowers HbA1c 0.57% (6 mmol/mol)1 – Has greater effect if > 150 mins week1 – Combined with AET may be more effective than AET alone (muscle mass) in reducing VAT2 – New trial underway-Washburn et al Contemp Clin Trials July 2012
  • Metabolic/Weight Losseffects Aerobic training• The more you do, the harder you go, the more you get1, 2 but effects are modest2• Increased physical activity and fitness improves health risk independent of weight1,2 but does not completely alleviate effects of weight1• Unfit lean men double risk mortality vs fit lean men3 (1.8/1000 man yrs vs 3.6)• Unfit men with waist <87cm higher mortality than fit men waist > 99cm (7.8/1000 man years vs 1.9)3• In DM unfit men of all weight categories 2.7-2.8 x mortality of those with high fitness levels and normal weight4• Limited data on those with BMI > 354, 5 1. Jakicic Obesity Dec 2009 2. Shaw K. Cochrane Database Syst Rev 2009 3. Lee CD Am J Clin Nutr 1999. 4. Church
  • Metabolic/Weight Loss effects Aerobic training• Typically 0.5-3kg weight loss with physical activity alone1• If supervised activity 45mins/daily for 16 months M lost 5.2kg v 0.5kg no exercise, W 0.6kg increase vs 2.9kg increase2• Effect of exercise interventions less than that if dietary interventions, 4kg vs 7.2kg at 1 year 1, 3• Combined intervention more effective still in short term studies 1, 4 0.6% placebo vs 8.4%/5.5% (M/ F) exercise vs 11.4%/7.5% combined 1. Jakicic Obesity Dec 2009 2. Donnelly Arch Int Med 2003 3. Wood PD NEJM 1988 4. Hagan Med Sci Sports Exerc 1986
  • Effects of Physical activity (aerobic) on long term weight loss/maintenance• Following weight loss 33-50% lost weight is regained in 12-18 months1• Physical activity may be critical in weight loss maintenance2• Those maintaining 10% weight loss at 24 months reported performing 275 minutes of activity above baseline levels2 (338 mins vs 63 mins)• Those who failed to maintain weight loss increased by 74 mins/week (128 mins vs 54 mins)2.• NWCR-those who maintained 13.6kg WL > 12 months reported >2,800kcal/wk of LTPA3• 76% of those who maintain weight loss report using physical activity as a WL strategy4 1. Jakicic Obesity Dec 2009 2. Jakicic Arch Int Med 2008 3. KlemAm J Clin Nutr 1997 4. Kayman Am J Clin Nut 1990
  • Exercise and prevention of weight gain• Australian Longitudinal study of womens health1: – 8726 18-23 yo F followed for 4 yrs – 41% gained ≥ 5% BW – Sitting > 33hrs/wk increased risk of weight gain by 20%• Healthy Worker Project2 – avge weight gain 0.6kg F and 0.4kg M over 2 yrs – 1 extra walking session/week reduced wt of 0.8kg F and 0.4kg M1. Ball K Int J Obes Relat Metab Disord 2002 2. French S Int J Obes Relat Metab Disord 1994
  • HIT (Panorama)• All out intervals > 90% VO2 peak, seconds to minutes with recovery period• Classically Wingate Test-30s all out vs high force on cycle ergometer 4-6 rpts with 4 min recovery• Used 3x weekly for 2-6/52 – At 2/52 2x duration effort at 80% base VO2 peak (26-51 mins) – Improves oxidative capacity mitochondrial enzymes 15-35% (euivalent to 10.5 hrs endurance training), increases GLUT-4 expression and muscle glycogen• Not used as weight loss strategy but
  • Summary-Activity/Exercise and obesity• The more you do and the harder you do it the more weight loss you get• Health benefits accrue from improved fitness as well as weight loss• Required levels of activity are more than most suppose• Most people struggle to achieve activity targets so strategies targeted at improving adherence required• The more contact people have the better they do
  • Studies that help us in real worldCounterweight Look AHEAD• www.counterweight.org • Diabetes Care 30:1374-1383,• Primary care led 2007• OMA training practice nurses • Obesity 14: 737-752 2006 in 20 practices • Arch Int Med 170: 1566-75• Groups (1 hrs) and 1:1 2010 (10-30 minutes each) • 0-6months: weekly visits, 3• 6 appointments in 3 months, group, 1x1:1. then at least quarterly • 7-12 months: 3 visits/m, 2• Lifestyle but pharmacotherapy group, 1x 1:1 (?Orlistat) available • 2-4 yrs: 1 face to face 1:1/m,• Links with supporting 1 x email/phone, refresher physician/dietitian groups/ campaigns • 5+yrs: monthly individualised contact/refresher groups/campaigns
  • What do they have in Common?• Based on evidence of what works• Clear structure to programme• Emphasis on motivation and engagement of patient• Use of goal setting and structured meal plans with calculated energy deficits• More frequent contact than usually afforded in everyday practice• The use of pharmaceutical agents if lifestyle alone did not achieve goals
  • What did they achieve?Counterweight• 47.9% with 1 year follow up data• Mean weight change -3.0kg• 30% had 5% weight loss (40% high attenders)• Estimated ↓ 6.3% of prescribing costs (8.4% in high attenders)• Savings cover 40% of programme costs
  • What did they achieve?Look AHEAD 1 yr • Look AHEAD 4 year• 97.1% 1 year follow up • 93% assessed in each of exam the 4 years• Mean 8.6% weight loss • Mean 6.15% WL (0.88% (0.7% C) control)• 37.8% had > 10% weight • HbA1c  0.36% ( 0.09 % loss (3.2% control) controls)• 68% > 5% weight loss • Less medication use-if no• HbA1c ↓ 7.3→ 6.6% OHG at baseline only 42% (↓0.14% C), use of using at 4 yrs vs 67% in medicines ↓ 7.8% (↑ 2.2% controls C), ↓ BP 7/3, ↓TG and cholesterol and ↓ % with MS 93.6→78.9%)∀ ↑ fitness 20.9 vs 5.8%
  • Look AHEAD good news• Percentage of people meeting all 3 treatment goals for BP, HbA1C and LDL – 10.8→23.6% ILI vs 9.5→ 16.0% C ↑ fitness and ↓ weight in controls – Controls got baseline education and 3 group sessions in one year and this was enough for substantial improvements from baseline
  • OK-some drugs• GLP-1• Orlistat• Phentermine/Topiramate Phase 3 studies underway-awaiting approval• Tesofensine –phase 3 x2 underway• Bupropion/Naltrexone, Buproprion/Zonisamide- awaiting approval• Pramlintide & combinations
  • Orlistat license• BMI > 30 or >28 with risk factors• Need to lose 2.5kg prior to treatment removed from license• Need to lose 5% bodyweight at three months to continue treatment long- term• Reconsider if significant regain occurs at any time• NICE recommendation in 2001
  • Proportion of patients achieving beneficial weight loss with Orlistat over one year (NGT)Patients (%) 100 Placebo + diet (n=340) p<0.05 Orlistat + diet (n=343) 80 68.5% (ITT population) p<0.05 60 49.2% 38.8% 40 17.7% 20 0 ≥5% ≥10% Weight loss (%) Adapted from Sjöström. Lancet 1998; 352: 167-172
  • Proportion of patients with T2Dachieving beneficial weight loss with Orlistat over one year Taken from Miles JM, Diabetes Care 2002;25(7):1123-8 and Kelley DE, Diabetes Care 2002;25(6):1033-41.
  • Weight control is more difficult to achieve in patients with type 2 diabetes Diet-treated Drug-treated Non-diabetic diabetic diabetic 0Change in BMI (kg/m2) –2 –4 –6 p<0.01 vs non-diabetic –8 –10 Adapted from Khan et al. Reprinted with permission from the North American Association for the Study of Obesity © 2000. Obes Res 2000; 8: 43–8
  • UK Orlistat Multimorbidity Study Improvements in risk factors Total LDL Sys Dias OGTT Chol Chol BP BP ScoreOrlistat -0.12 -0.3 -6.0 -5.5 -0.37Placebo +0.16 -0.02 -2.3 -3.1 +0.09 All differences at least p<0.05
  • Orlistat-Summary• In NGT patients approx 4-6kg extra weight loss with orlistat vs. placebo short term.• 70% ≥ 5% WL and 40% ≥ 10% WL• In T2DM approx 50% of this• 10, 631 patietns in 16 studies 1-4 yrs in Cochrane review 2009, with WL approx 2.9 kg v placebo in these1• Improves cardiovascular risk factors, glycaemia to small extent1.• No CV or mortality data11.Padwal; Cochrane Database Syst Rev 2009
  • Liraglutide Astrup Lancet 2009 • GLP-1 analogue • 1.2-3.0mg vs placebo and orlistat over 20/52 • WL = 4.8kg (1.2mg) vs 5.5.kg (1.8mg) vs 6.3kg (2.4mg) vs 7.2 kg (3.0mg) vs 2.8kg (placebo) vs 4.1 kg (orlistat) at 20/52 • 76% with 3.0mg lost > 5%, vs 41% orlistat vs 30% placebo • Withdrawal rates 19% placebo, 11-22% liraglutide and 17% orlistat. Nausea in 24-47% in those on liraglutide • At 2yrs WL 7.8 vs 5.4 kg Liraglutide vs Orlistat (p=0.09) with SBP 12.5 vs
  • Topiramate/Phentermine- Qnexa• Topiramate-GABA agonist, unkown action in obesity.  SE monotherapy• Phentermine-NA lateral hypothalamus, β2-stumulation, appetite• Combination at 92mg/15mg and 46mg/7.5mg preparations in Phase 3 studies-EQUATE, EQUIP, CONQUER• CONQUER Lancet 2011, Gadde et al• 2487 patients, BMI 27-45 plus 2 comorbidiities• WL 1.4 kg vs 8.1 kg vs 10.2kg (9.8%) with 70% > 5% WL vs 21% placebo  depression and anxiety A/Es in high dose group vs low dose group vs placebo (7% vs 4% vs 4%)
  • Tesofensine• Tesofensine – inhibits NA/DA, 5HT re-uptake presynaptically and studied in AD and PD – Phase IIb studies 10.6% WL 24 weeks in 1 mg dose but increased heart rate 7.4bpm
  • Bupropion Combinations-Under RV FDA • Buproprion inhibits reuptake DA and NA and activates POMC neurons,  α-MSH release,  appetite • Naltrexone blocks β-endorphin inhibition of POMC α-MSH release • Zonisamide-anit-epilepsy with DA and 5HT activity • Combined with Naltrexone SR 32mg/Bupropion SR 360 mg = Contrave • Phase III studies: COR-I (Greenaway Lancet 2010), II; COR-BMOD, COR-Diabetes – 552 with DM and obesity, A1c 7-10% – WL 5% vs 1.8% – A1c  0.6% • With Zonisamide ? Greater WL in Phase
  • Pramlintide• With Metreleptin-Phase II, 12.7% WL at 20/52• With Sibutramine• With Phentermine• With Exenatide
  • Summary-Drugs• Orlistat only drug with long term license and profile• Liraglutide looks promising• Others coming through but not greatly increased weight loss over current agents to date. Newer centrally acting drugs in development• Long term use is required and attrition limits effectiveness• Need for hard endpoint studies
  • Adiposity signallingSchwarz Nature vol 404 6 April 2000
  • The hypothalamus in weight control Schwarz Nature vol 404 6 April 2000
  • Integrating adiposity and satiety signalsSchwarz Nature vol 404 6 April 2000